The number of drugs subject to negotiations under the Price-Volume Agreement (PVA) system among cold medicines and antibiotics whose usage increased explosively with the rise in the number of confirmed COVID-19 patients, is expected to be small.

When the National Health Insurance Service applied the correction plan it had devised after collecting industry opinion, results showed that little more than 10 items were subject to negotiations.

Such results will be applied around the end of April when the government monitors PVA ‘Type C’ drugs.

According to industry sources on the 8th, the NHIS corrected the use amount of about 2,600 cold medicines and antibiotics whos